Cross-source evidence timeline

Mecasermin research timeline

Follow 32 selected, directly cited source records from April 23, 1997 through November 5, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

32Selected records
18Source years
3Evidence lanes
November 5, 2026Latest source date

Source year

2026

3 records
  1. Literature metadata

    Mecasermin for the treatment of Rett Syndrome: a systematic review.↗

    PubMed lists PMID 41174329 in Neurogenetics as Journal Article, Systematic Review, with publication-date metadata of 2025-11-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00903110↗

    PeptideScanner retained ClinicalTrials.gov record NCT00903110 at 2026-11-16T17:35:13.282Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  3. Literature metadata

    Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment.↗

    PubMed lists PMID 36269524 in Stem cell reviews and reports as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT02636270↗

    PeptideScanner retained ClinicalTrials.gov record NCT02636270 at 2026-11-16T17:35:13.282Z. Its registry update date was 2024-02-28, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2023

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00571727↗

    PeptideScanner retained ClinicalTrials.gov record NCT00571727 at 2026-11-16T17:35:13.282Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2022

3 records
  1. Literature metadata

    Mecasermin for primary insulin-like growth factor-1 deficiency.↗

    PubMed lists PMID 36479333 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2022-12-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Mecasermin.↗

    PubMed lists PMID 18481900 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, Review, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.↗

    PubMed lists PMID 19707272 in Therapeutics and clinical risk management as Journal Article, with publication-date metadata of 2009-08-03 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00516386↗

    PeptideScanner retained ClinicalTrials.gov record NCT00516386 at 2026-11-16T17:35:13.282Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  2. Literature metadata

    Efficient process development for high-level production, purification, formulation, and characterization of recombinant mecasermin in Escherichia coli.↗

    PubMed lists PMID 32692415 in Biotechnology and applied biochemistry as Journal Article, with publication-date metadata of 2020-08-07 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.↗

    PubMed lists PMID 29750649 in Journal of pediatric endocrinology & metabolism : JPEM as Case Reports, Journal Article, with publication-date metadata of 2018-06-27 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

2 records
  1. Literature metadata

    Recombinant production of mecasermin in E. coli expression system.↗

    PubMed lists PMID 26339260 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2014 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01406444↗

    PeptideScanner retained ClinicalTrials.gov record NCT01406444 at 2026-11-16T17:35:13.282Z. Its registry update date was 2020-07-17, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2019

2 records
  1. Literature metadata

    Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.↗

    PubMed lists PMID 18363546 in Expert opinion on drug metabolism & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008-03 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.↗

    PubMed lists PMID 29695048 in International journal of molecular sciences as Case Reports, Journal Article, Review, with publication-date metadata of 2018-04-24 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

2 records
  1. Literature metadata

    Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.↗

    PubMed lists PMID 15777106 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01777542↗

    PeptideScanner retained ClinicalTrials.gov record NCT01777542 at 2026-11-16T17:35:13.282Z. Its registry update date was 2018-03-26, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2017

2 records
  1. Literature metadata

    Mecasermin rinfabate.↗

    PubMed lists PMID 17380212 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2007-03 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01438086↗

    PeptideScanner retained ClinicalTrials.gov record NCT01438086 at 2026-11-16T17:35:13.282Z. Its registry update date was 2017-03-30, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2016

1 record
  1. Literature metadata

    Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome.↗

    PubMed lists PMID 22986916 in Hormone research in paediatrics as Case Reports, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-13 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2015

1 record
  1. Literature metadata

    Desensitization to mecasermin in an insulin-like growth factor 1-deficient patient.↗

    PubMed lists PMID 25843163 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Case Reports, Letter, with publication-date metadata of 2015-04-03 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2012

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01446783↗

    PeptideScanner retained ClinicalTrials.gov record NCT01446783 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-11-20, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  2. Literature metadata

    Mecasermin (recombinant human insulin-like growth factor I).↗

    PubMed lists PMID 19198769 in Advances in therapy as Journal Article, Review, with publication-date metadata of 2009-01-28 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01588093↗

    PeptideScanner retained ClinicalTrials.gov record NCT01588093 at 2026-11-16T17:35:13.282Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was mecasermin.↗

Source year

2009

1 record
  1. Literature metadata

    Allergic reaction to mecasermin.↗

    PubMed lists PMID 19663134 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Case Reports, Letter, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2007

2 records
  1. Literature metadata

    USAN Council. List No. 419. New names. Mecasermin.↗

    PubMed lists PMID 10576957 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Mecasermin Tercica.↗

    PubMed lists PMID 16625824 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2006-04 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2006

2 records
  1. Regulatory

    Federal Register notice E6-12571↗

    The Federal Register published notice E6-12571, attributed to FDA and its parent HHS department, on 2006-08-03. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

  2. Regulatory

    Federal Register notice E6-9138↗

    The Federal Register published notice E6-9138, attributed to FDA and its parent HHS department, on 2006-06-13. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Source year

2005

1 record
  1. Regulatory

    Drugs@FDA application BLA021839↗

    The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.↗

Source year

1998

1 record
  1. Regulatory

    Federal Register notice 98-7053↗

    The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗

Source year

1997

1 record
  1. Regulatory

    Federal Register notice 97-10541↗

    The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.↗